Market growth no longer covers the gaps it once did. The question now is where a particular pharmacy actually makes its money, and which forces will change that.
Policy, pricing, and competition are moving several layers of specialty pharmacy economics at once. The owners who see each layer clearly will know where to act.
Specialty, infusion, and compounding pharmacy remains active private equity territory. McKinsey counted 25 to 50 transactions across retail, pharmacy, and specialty medication in 2025, mostly horizontal deals combining specialty and infusion businesses. But market growth no longer covers the gaps it once did. Specialty drugs’ share of dispensing revenue has plateaued for three straight years, according to the Drug Channels Institute’s 2026 report.
For a sponsor or a CEO, that shifts the question from how fast the market grows to where a particular pharmacy actually makes its money, and which of the forces now in motion will change that.
What the pharmacy pays for the drug, and the cheapest location to fill each order once shipping is included.
What the pharmacy is paid for each fill: the payer or PBM rate, net of fees charged after the fill, or the cash price for patients paying directly.
Limited-distribution access, data and service fees, and rebate thresholds, and what crossing each threshold is worth.
Clinical time, patient support, shipping, cold chain, and collections.
A margin change can start in any of these layers. An owner who sees only one or two of them cannot tell which change is driving the result.
Pharmacy benefit manager reform. In February 2026, Congress enacted the most significant federal PBM reform in years, most of it taking effect in 2028 and 2029. In Medicare Part D, PBM pay will be separated from drug prices, rebates must pass through to plans, and plans must admit any willing pharmacy that meets their standard terms. Employer plans will also receive full rebate pass-through and new transparency reporting. The National Association of Specialty Pharmacy called the pharmacy protections a historic win after years of below-cost reimbursement and restrictive networks.
Reimbursement benchmarks. More reimbursement is moving toward methods based on what pharmacies actually pay for drugs, in Medicaid, some commercial plans, and cash-pay pharmacies. At the same time, manufacturers cut list prices on more than 30 brands, and net prices, not list prices, increasingly drive access and economics.
Direct-to-consumer prices. Manufacturers increasingly sell directly to cash-pay patients at deep discounts to list price, including through TrumpRx. Those programs set public reference prices that cap what pharmacies can charge cash patients and give payers a benchmark, and some fills bypass the pharmacy entirely. Where markups and fees are set as a percentage of list price, list price cuts also shrink margin dollars per fill. Whether margin holds depends on whether acquisition cost falls as fast as the selling price.
340B. 340B sales now exceed Medicaid outpatient drug sales, and more than 40 manufacturers have restricted contract-pharmacy discounts. A revised federal pilot that replaces upfront 340B discounts with rebates is set to begin in January 2027 for drugs selected for Medicare price negotiation, though hospitals have sued to block it and a House bill would delay it. The pilot covers a small share of 340B sales, but pharmacies with contract-pharmacy revenue should model what a broader rebate approach would do to cash flow.
Competition for volume. Pharmacies affiliated with the three largest PBMs took 68 percent of specialty drug revenue in 2023, up from 54 percent in 2016, according to the Federal Trade Commission. The largest PBMs have also favored their own private-label biosimilars, and payers and health systems are investing in hospital specialty pharmacy programs that compete with independents for the same patients.
Independent specialty pharmacies tend to compete on specialization: the therapies, conditions, and manufacturer programs they handle well. A survey of 46 specialty pharmacy executives by Health Industries Research Companies found exactly that pattern, with PBM-owned pharmacies competing on payer alignment and health system pharmacies on provider integration.
CMS has proposed a Medicare model, known as GUARD, that would tie Part D rebates to drug prices in other wealthy countries from 2027 if finalized. CMS itself acknowledged that manufacturers might respond by changing distribution channels, and the specialty pharmacy association warned that manufacturers could narrow limited-distribution networks to fewer pharmacies.
For a PE-backed independent, which limited-distribution drugs it holds, and how secure that access is, belongs in the valuation.
Growth is shifting toward drugs administered in clinics and infusion settings. The American Society of Health-System Pharmacists projects overall U.S. drug spending to rise 10 to 12 percent in 2026, passing $1 trillion, with spending on clinic-administered drugs rising 14 to 16 percent. Pharmacies positioned in infusion and physician-office channels stand to gain; those dependent on a narrowing set of oral specialty therapies face more pressure.
The pharmacies that come through this period well will be the ones with a full handle on their business from a margin perspective: which layer each change hits, and for which therapies, payers, and patients. That understanding tells them where to act, with patients, suppliers, payers, and manufacturers, and which action to take: renegotiate a payer contract, change where and how they buy, shift effort toward the therapies and referral sources that earn their keep, or reach out to patients at risk of leaving. Without it, they react to policy headlines instead of their own numbers.
Measurement is only the start. The analytics that pay off are the ones tied to actions the business can take. For a specialty pharmacy, those include:
Route each order to the lowest-cost location that has the drug in stock, with shipping and cold chain included.
Flag the payers and therapies where reimbursement, after post-fill fees, falls below the cost to acquire and dispense, and take them to contract renegotiation.
Forecast which therapy lines sit just short of a manufacturer’s threshold, and alert purchasing and contracting teams before the quarter closes.
Track referral volume and conversion by prescriber and clinic, and flag declines early so liaisons can follow up before the volume is gone.
Track each limited-distribution product’s share of margin, and build the performance and outcomes data manufacturers use when they decide which pharmacies stay in their networks.
Dispensing, acquisition cost, reimbursement, post-fill fees, rebates, and referral data sit in separate systems, and each acquired pharmacy brings its own definitions. The first step is a governed data foundation: a semantic layer and a shared model of fills, therapies, payers, prescribers, and locations that holds across every acquisition.
The second step is economics. That means attributing a margin change to the layer that caused it, separating a lower reimbursement benchmark from a shift in payer or therapy mix, and forecasting rebate positions and the value of limited-distribution access. A dashboard is only the last step, the place where that work becomes visible to the people who act on it.
The same foundation also changes who can do the analysis. With clear data governance in place, defining who owns each data domain, who stewards its definitions and quality, and who maintains the systems as custodian, pharmacy operations, revenue cycle, and finance teams no longer have to queue every question behind IT. A well-built semantic layer, AI tools that work against it, and the right training let them build the analytics they need, while IT concentrates on keeping systems reliable and available.
We have done this kind of work before, including cutting costs by about 40 percent in a core part of a PE-backed national pharmacy specializing in fertility medications and lifting its customer retention 10 percent in a month, as well as work on the manufacturer side of rebate contracts.
The method carries over to oncology, rare disease, and infusion; the numbers have to be measured again, because payer mix, limited-distribution access, and clinical program requirements differ.
The specialty pharmacies that come through this period best will not be the ones that guessed right about policy. They will be the ones that can see, layer by layer, what is moving their margin, and act before it shows up in the financials.
A short conversation is enough to see which of these measures your data can support today, and where the foundation needs work.
A read on how policy and pricing changes net out for a portfolio pharmacy, and what belongs in the value creation plan.
Compare NotesA governed view of margin by layer, therapy, and payer, and the economics to know where to act.
Map the Margin